Understanding Gastroparesis

Understanding Gastroparesis

Gastroparesis is a gastrointestinal disorder characterized by delayed stomach emptying, resulting from weak or uncoordinated muscle movements in the stomach. The condition is classified as complicated when it involves severe symptoms, underlying chronic illnesses, or related complications that make management more challenging and increase the risk of health deterioration. Common triggers include diabetes, neurological diseases, and past abdominal surgeries. Symptoms typically include nausea, vomiting, bloating, early satiety, abdominal pain, and in more advanced cases, can lead to malnutrition or dehydration due to impaired digestion.

Management of gastroparesis involves a multifaceted treatment approach, including dietary adjustments, medications, and lifestyle changes. Patients are often advised to eat smaller, more frequent meals, avoid foods high in fat and fiber, and may receive medications that enhance stomach motility or reduce nausea. For severe cases, feeding tubes, intravenous nutrition, or surgical interventions may be required. Proper control of underlying conditions like diabetes is essential to avoid worsening symptoms. Timely diagnosis and personalized treatment strategies are key to symptom control, preventing complications, and improving patient quality of life.

Track the trends in DCM & more—explore the data visually

https://www.delveinsight.com/infographics/gastroparesis-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

Gastroparesis Epidemiological Segmentation (2020–2034, 7MM)

• Total Prevalent Cases
  
  

• Diagnosed Prevalent Cases
  
  

• Cause-Based Segmentation
  
  

• Age-Wise Distribution
  
  

• Gender-Specific Cases
  
  

• Number of Treated Cases
  
  

Gastroparesis Epidemiology

• The estimated number of diagnosed gastroparesis cases in the U.S. is around 720,000.
  
  

• Approximately 4.5 million people in the U.S. experience gastroparesis-like symptoms.
  
  

• About 70% of diagnosed patients are women, while 30% are men.
  
  

From insights to impact—read the full report now : Click Here

Gastroparesis Market Overview

• Market Size (2023, 7MM): Approximately USD 240 million

Market Drivers

• Upcoming novel treatment launches are expected to expand therapeutic options.
  
  

• Interest in disease-modifying therapies is rising, offering a shift from purely symptomatic management.
  
  

• Ongoing research is fueled by growing demand for innovative and effective treatments.
  
  

• Increasing patient awareness and demand are prompting new drug development.

One graphic, all the essentials— Click to explore

Market Challenges

• Existing treatments are largely symptom-focused, limiting overall effectiveness.
  
  

• Pricing and reimbursement challenges may restrict access to newer therapies.
  
  

• The complex nature of the disease complicates diagnosis and therapeutic planning.
  
  

• Low awareness and lack of approved treatments often lead to delayed diagnosis and care.
  
  

Emerging Therapies for Gastroparesis

• Tradipitant
  
  

• NG101
  
  

• CIN-102
  
  

• Additional candidates in development
  
  

Leading Companies in the Gastroparesis Market

• Vanda Pharmaceuticals
  
  

• Neurogastrx
  
  

• CinDome Pharma
  
  

• And others
  
  

Infographic highlights, report insights—grab your copy today : 

https://www.delveinsight.com/report-store/gastroparesis-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr